2018
Correlates of Perceived Stress in Parents of Teens with Type 1 Diabetes
WHITTEMORE R, DELVY R, COLEMAN J, KATO B, AMBROSOLI J, MAURAO M, ZINCAVAGE R, MARCEAU L. Correlates of Perceived Stress in Parents of Teens with Type 1 Diabetes. Diabetes 2018, 67 DOI: 10.2337/db18-854-p.Peer-Reviewed Original ResearchParents of teensDepressive symptomsType 1 diabetesElevated depressive symptomsYears of ageMultivariate model analysisElevated anxiety symptomsDaily regimenMean A1CT1D durationDiabetes careMore episodesMultivariate correlatesParenting stressPsychosocial factorsYears durationSecondary analysisInsulin pumpType 1Bivariate correlatesParent depressionHealth diagnosisSymptomsPsychosocial correlatesAnxiety symptomsA172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)
Conway B, Dore G, Altice F, Litwin A, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT). Journal Of The Canadian Association Of Gastroenterology 2018, 1: 299-300. PMCID: PMC6508009, DOI: 10.1093/jcag/gwy008.173.Peer-Reviewed Original ResearchEnd of treatmentImmediate treatment groupHCV reinfectionProbable reinfectionHCV RNATreatment groupsLong-term response ratesHepatitis C virus genotypesEBR/GZRHCV reinfection ratesUndetectable HCV RNARisk of reinfectionC virus genotypesInterferon-free HCV treatmentRate of reinfectionFixed-dose combinationPost-treatment samplesRecurrent viremiaReinfection incidenceAgonist therapyDaily regimenHCV therapyHCV treatmentVirologic failureHCV GT1
2011
A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus
Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV. A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. Endocrine Practice 2011, 17: 862-866. PMID: 21550949, DOI: 10.4158/ep11031.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHospitals, PediatricHospitals, UniversityHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulin DetemirInsulin Infusion SystemsInsulin, IsophaneInsulin, Long-ActingInsulin, Short-ActingMaleConceptsRapid-acting insulin analoguesInsulin detemirNPH insulinYounger patientsA1c levelsInitial treatmentInsulin dosesNew-onset type 1 diabetes mellitusInsulin analoguesBasal/bolus insulinTotal daily insulin dosesType 1 diabetes mellitusInsulin injection treatmentPump-treated patientsDaily insulin dosesHemoglobin A1c levelsTwice daily regimenEffective initial treatmentSevere hypoglycemic eventsNew-onset T1DMInsulin pump therapyDetemir insulinDaily regimenInsulin regimenDiabetes mellitus
2007
Levemir® Early Clinical Experience Case Series
Mayerson AB. Levemir® Early Clinical Experience Case Series. Endocrinology And Metabolism Clinics Of North America 2007, 36: 45-52. PMID: 17881331, DOI: 10.1016/s0889-8529(07)80007-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInsulin detemirCase seriesDiscontinuation of treatmentMean weight lossLarge observational studiesType 2 diabetesDaily regimenFinal followTreatment discontinuationGlycemic controlTreatment initiationHypoglycemic episodesA1C valuesCase reportThird followObservational studyDetemirMean decreasePatientsSpecial interventionDoctor's officeWeight lossObservation periodDiscontinuationRegimen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply